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RESEARCH ARTICLE
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Abstract
Purpose: S-[11C]-methyl-L-cysteine ([11C]MCYS) has been claimed to offer higher tumor
selectivity than L-[methyl-11C]methionine ([11C]MET). We examined this claim in animal models.
Procedures: Rats with implanted untreated (n = 10) or irradiated (n = 7, 1 × 25 Gy, on day 8) orthotopic
gliomas were scanned after 6, 9, and 12 days, using positron emission tomography. Rats with striatal
injections of saline (n = 9) or bacterial lipopolysaccharide (n = 9) were scanned after 3 days.
Results: Uptake of the two tracers in untreated gliomaswas similar. [11C]MCYSwas not accumulated in
salivary glands, nasal epithelium, and healing wounds, in contrast to [11C]MET, but showed 40%higher
accumulation in the healthy brain. Both tracers showed a reduced tumor uptake 4 days after irradiation
andminor accumulation in inflamed striatum. [11C]MCYS indicated higher lesion volumes than [11C]MET
(untreated tumor + 47 %; irradiated tumor up to + 500 %; LPS-inflamed striatum + 240 %).
Conclusions: [11C]MCYS was less accumulated in some non-tumor tissues than [11C]MET, but
showed lower tumor-to-brain contrast.
Key words: Amino acids, Brain tumors, Inflammation, Brain, Positron emission tomography,
Small animal imaging
Introduction
The radiolabeled amino acid L-[methyl-11C]methionine
([11C]MET) is widely used for tumor imaging. However,
[11C]MET is taken up not only by tumors but also by
various other lesions [1–3]. For this reason, there is much
interest in the development of positron emission tomography
(PET) tracers with greater tumor specificity than [11C]MET.
A successful alternative is the amino acid analog O-2-
[18F]fluoroethyl-L-tyrosine ([18F]FET) [4]. Another amino
acid analog which has been proposed for the same purpose is
S-[11C]methyl-L-cysteine ([11C]MCYS) [5, 6]. MCYS is a
naturally occurring derivative of the amino acid L-cysteine.
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doi.org/10.1007/s11307-017-1137-z) contains supplementary material,
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Large amounts of this substance are present in many
vegetables [7, 8]. Biodistribution studies in nude mice
indicated a somewhat higher uptake of [11C]MCYS in
Hepa1–6 tumors compared to [11C]MET, but a lower uptake
in turpentine-induced sterile inflammations [5]. Thus,
[11C]MCYS was claimed to offer superior differentiation of
tumor from inflammation and to have considerable potential
as an oncologic PET tracer.
In order to examine this claim, we performed longitudinal
PET studies with [11C]MCYS and [11C]MET in various
animal models: immune-competent rats with orthotopically
implanted gliomas (see [9]) which were either untreated or
received radiotherapy, rats which were injected with bacte-
rial lipopolysaccharide (LPS) in the right striatum (see [10]),
and sham-injected rats which received physiological saline
instead of LPS. Our data indicate that [11C]MCYS accumu-
lates less in some non-tumor tissues (salivary glands,
Harderian glands, nasal epithelium, healing wounds) than
[11C]MET, but shows a higher uptake in the healthy brain,
resulting in lower tumor-to-brain contrast of [11C]MCYS
scans. Moreover, irradiation of gliomas results in an acute,
5- to 6-fold increase of the volume with significant
[11C]MCYS uptake which does not reflect the presence of
viable tumor cells. Based on these results, [11C]MCYS and




L-[methyl-11C]methionine was prepared by methylation of
L-homocysteine thiolactone with [11C]methyl iodide. The
radiochemical yield was 60 %, and specific activities were
greater than 2 TBq/mmol [1]. S-[11C]methyl-L-cysteine was
synthesized by [11C]methylation of L-cysteine [5], using
[11C]methyl triflate rather than [11C]methyl iodide.
2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) was produced
by the Hamacher method [11]. Bacterial lipopolysaccharide
(LPS) was purchased from Sigma Aldrich (cat.no. L6529).
Animals
All actions with experimental animals were performed by
licensed investigators. The study protocol was approved by
the Institutional Animal Care and Use Committee of the
University of Groningen (protocol 6561A). Male Wistar
rats were acquired from Harlan. They were housed at
21 ± 2 °C under a fixed 12-h light–dark regime. Standard
laboratory chow and water were available ad libitum. The
animals received a special high-energy diet on the day of
the surgery and the following day, as well as 2 days before
and after brain irradiation (see below). After a 7-day
acclimation period, the animals were randomly divided in
five different groups (see Table 1): 1 (Pilot): C6 glioma
cells were stereotactically injected in the right striatum.
[11C]MCYS and [11C]MET scans were made after 8 days
and a [18F]FDG scan after 15 days; 2 (Tumor-bearing,
untreated): C6 glioma cells were injected as in group 1,
but [11C]MCYS and [11C]MET scans were made after 6, 9,
and 12 days; 3 (Tumor-bearing, radiotherapy): As group
2, but the lesion-containing hemisphere was irradiated after
8 days; 4 (Saline-injected): 2 μl of physiological saline was
stereotactically injected into the right striatum and
[11C]MCYS and [11C]MET scans were made after 3 days;
5 (LPS-injected): As group 4, but 2 μl of a solution of LPS
in saline was stereotactically injected into the right striatum
in order to induce neuroinflammation.
Stereotactic Injection of C6 Cells
Rats from groups 1, 2, and 3 were anesthetized by
intraperitoneal injection of ketamine (25 mg/kg) and
medetomidine (0.2 mg/kg) and placed in a stereotactic
frame. Eye cream was applied and heating pads were used
to maintain body temperatures close to the normal value.
During surgery, the rats breathed oxygen from a nose
mask, and pO2 and heart rate were continuously moni-
tored. A longitudinal incision was made along the medial
line of the skull, the skin and fascia were pushed aside,
and the skull was exposed. A hole was drilled at the
coordinates of the striatum (from Bregma A = − 0.30;
L = + 3.0), until the dura became visible and could be
opened [12]. Using a Hamilton injection needle, 5 × 105
C6 cells in 5 μl of sterile saline were slowly injected (in
10 min), at a depth of − 5.0 from Bregma. Before
injection, the needle was wiped with 70 % alcohol and
saline to avoid contamination of host tissue with tumor
cells outside the desired area. The syringe was left in
position for an additional 5 min and was then withdrawn.
The skin was closed and saline was injected subcutane-
ously to prevent dehydration. Bupivacaine (5 mg/ml) was
locally applied to suppress pain. Anti-sedan was used to
wake up the animal and 0.03 mg/kg of s.c. Temgesic was
given after 30 min.
Irradiation
Group 3 received special care to reduce the discomfort of
radiotherapy as much as possible, starting 2 days before
irradiation. This special treatment involved the feeding of a
high-energy diet, the addition of sucrose to the drinking
water, and the application of Bepanthen® cream to the skull
after radiotherapy. On the day of treatment, rats were
anesthetized by intraperitoneal injection of ketamine
(25 mg/kg) and xylazine (20 mg/ml). Eye cream was
applied, and the animals were placed in a special frame
containing a lead collimator which shielded the non-lesioned
hemisphere and all tissues outside the brain, including the
eyes and the parotid glands. The right hemisphere was
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irradiated with a single X-ray fraction of 25 Gy. After
irradiation (about 18 min), the rats were aroused with Anti-
sedan, returned to their cages, and allowed to recover. The
entire procedure was finished within 30 min.
Stereotactic Injection of Saline or LPS
Rats were injected with saline or LPS using the same
procedure as for injection of C6 cells, but the injected
volume was 2 μl and the sterile saline contained either
nothing (group 4) or bacterial lipopolysaccharide (Escher-
ichia coli 020:B6, 0.5 μg/μl, group 5).
PET Imaging
On each scanning day, rats were anesthetized with isoflurane
(2 % in medical air, flow rate 1 to 2 ml/min). [11C]MCYS or
[11C]MET was injected via a tail or penile vein. A dynamic
emission scan of 60 min was made with a Siemens/
Concorde Focus 220 camera, using a list mode protocol.
Two rats were scanned simultaneously, in transaxial position
with their brains in the field-of-view. In some animals, a
static rather than a dynamic scan was made for logistic
reasons, lasting from 30 to 60 min after tracer injection.
Finally, a transmission scan was made (515 s), using a Co-
57 point source. Data from this scan were used for the
correction of attenuation and scatter of 511-keV photons by
tissue. During all scans, body temperature of the animals
was maintained by heating mats, whereas heart rate and
blood oxygenation were continuously monitored. A
[11C]MCYS scan and a [11C]MET scan were made of each
animal on each scanning day, with an interval of at least 2 h.
The list mode data of the emission scans were reframed into
a dynamic sequence: 6 × 10 s, 4 × 30 s, 2 × 60 s, 1 × 120 s,
1 × 180 s, 4 × 300 s, 3 × 600 s frames. Images were
reconstructed employing ordered subset expectation maxi-
mization (OSEM 2D with Fourier rebinning, four iterations,
and 16 subsets). The final datasets consisted of 95 slices
with a thickness of 0.8 mm and an in-plane image matrix of
128 × 128 pixels. Voxel size was 0.5 × 0.5 × 0.8 mm. The
linear resolution at the center of the field-of-view was
1.5 mm. Data sets were corrected for decay, random
coincidences, scatter, and attenuation.
Data Analysis
Three-dimensional regions of interest (ROIs) were manu-
ally drawn in PET images, representing the tumor, LPS- or
saline-injected striatum, contralateral healthy brain, and the
wound on top of the skull. ROI volumes and levels of
radioactivity (mean and maximum within the ROI) were
calculated, using AsiPro® (Siemens). Tracer accumulation
was expressed as a standardized uptake value (SUV):
[tissue activity concentration (MBq/g) × body weight (g)/
injected dose (MBq)], assuming a specific tissue gravity of
1 g/ml. Images were smoothed with a Gaussian filter
(1.5 mm in both directions). The color scale of the images
was set from SUV 0 to 2 (± 10 %), in order to clearly
delineate the lesion. However, for visualization of LPS- or
saline-injected striatum with [11C]MET, the maximum had
to be set to SUV 1.4 (± 10 %). Care was taken to include
in the ROIs only planes that were located within the brain,
since wound tissue on top of the skull could strongly take
up [11C]MET, particularly at short intervals (3–6 days)
after surgery.
Statistics
Results reported in the Tables are expressed as mean ± SD.
Error bars represent SEM. Group differences were examined
using t test and two-way ANOVA, followed by a Bonferroni
correction, where applicable. A P value G 0.05 was
considered statistically significant.




















4 8 and 15 days – 0 278 ± 8 27 ± 17 21 ± 13
2. Tumor-bearing
(untreated)
10 6, 9 and 12 days – 0 314 ± 23 23 ± 12 24 ± 13
3. Tumor-bearing
(radiotherapy)








9 3 days – 0 283 ± 17 34 ± 19 28 ± 17
On all mentioned days, [11C]MET and [11C]MCYS scans were made in each rat, with exception of day 15 (group 1) when [18F]FDG was used
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Results
Group 1
The pilot study confirmed that inoculation of C6 cells led
to the formation of a tumor that was clearly visible after
8 days (volume ~ 60 μl). An [18F]FDG scan made in the
same rats after 15 days indicated the presence of tumors
with a volume of 451 ± 81 μl, filling almost an entire
cerebral hemisphere and starting to invade the rest of the
brain (Figure in Supplementary Evidence). Because of this
rapid growth, we decided to terminate our animals after 12
rather than 15 days. An interval of 8 days was selected for
the application of radiotherapy whereas [11C]MET and
[11C]MCYS scans in groups 2 and 3 were made at 6, 9,
and 12 days.
Group 2
[11C]MCYS and [11C]MET showed a similar uptake in
untreated tumors at 6, 8, or 9 days post inoculation (Table 2).
At 12 days, [11C]MCYS showed a 14 to 20 % higher uptake
than [11C]MET (Table 2). The uptake of [11C]MCYS in healthy
brain tissue was always 40 % higher than that of [11C]MET
(P G 0.0001, Table 2). As a consequence of this higher brain
uptake, tumor-to-brain ratios of [11C]MCYS were 20 to 30 %
lower than those of [11C]MET (P G 0.0001, Table 2).
Table 2. Tracer uptake in rats with untreated brain tumors













6 days p.i. 10 0.96 ± 0.17 1.00 ± 0.09 1.22 ± 0.29 1.24 ± 0.28 34 0.59 ± 0.07 0.83 ± 0.07*
8 days p.i. 4 1.24 ± 0.09 1.19 ± 0.03 1.76 ± 0.10 1.75 ± 0.20
9 days p.i. 10 1.26 ± 0.13 1.24 ± 0.13 1.92 ± 0.57 1.79 ± 0.40
12 days p.i. 10 1.18 ± 0.10 1.35 ± 0.13@ 1.77 ± 0.51 2.13 ± 0.43$













6 days p.i. 10 1.72 ± 0.24 1.31 ± 0.10* 1.96 ± 0.32 1.53 ± 0.35@ 10 1.61 ± 0.16 0.95 ± 0.13*
8 days p.i. 4 1.99 ± 0.16 1.40 ± 0.09# 2.46 ± 0.36 1.91 ± 0.27$
9 days p.i. 10 2.05 ± 0.20 1.45 ± 0.12* 2.61 ± 0.57 1.92 ± 0.39@
12 days p.i. 10 2.07 ± 0.28 1.59 ± 0.11* 2.59 ± 0.74 2.28 ± 0.46
Overall 34 1.95 ± 0.27 1.45 ± 0.15* 2.40 ± 0.60 1.91 ± 0.47*
Data for 8 days p.i. are from a separate pilot study. BWound^ refers to tissue on top of the skull. BMean ratio^ indicates SUVmean in tumor/SUVmean in brain
or SUVmean in wound/SUVmean in brain. BMax ratio^ indicates SUVmax in tumor/SUVmax in brain
P.i. post inoculation
*P G 0.0001, #P G 0.001, @P G 0.005, and $P G 0.05 indicate significant differences between [11C]MET and [11C]MCYS
Fig. 1 PET images of a single rat made 6 days after inoculation of tumor cells. (a) [11C]MET is strongly accumulated in the
healing wound (W) on top of the skull and also in submandibular gland (SG) in contrast to (b) [11C]MCYS. The tumor (T) is still
very small and barely visible.
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[11C]MET was strongly accumulated in parotid and sub-
mandibular glands, nasal epithelium, Harderian glands, and
healing wounds (including the injection spot in the skull),
but [11C]MCYS showed only minor accumulation in these
tissues (Fig. 1). At 6 days after surgery, [11C]MET was
significantly accumulated in the wound, in contrast to
[11C]MCYS (wound-to-brain ratio 1.61 ± 0.16 vs
0.95 ± 0.13, Table 2). This difference between the tracers
became smaller at later time points. Apparently, the surgical
trauma was gradually healed.
Tumor and wound tissue showed different tracer
kinetics (Fig. 2). After injection of [11C]MET, radioactivity
in the tumor slowly increased and reached a plateau
between 30 and 60 min. In the wound on top of the skull,
radioactivity peaked within 1 min and subsequently
showed a partial washout. During the static scans (30–
60 min), uptake of radioactivity in tumor and wound tissue
was about equal (Fig. 2a). After injection of [11C]MCYS,
radioactivity in the tumor reached a maximum between 3
and 15 min, whereas a minor washout was observed
between 15 and 60 min. Radioactivity in the wound
peaked at 2 min and subsequently showed a partial
washout. During the static scans, uptake of radioactivity
in the tumor was significantly greater than in the healing
wound (Fig. 2b).
Mean tumor sizes estimated from [11C]MCYS or
[11C]MET scans were linearly related (r = 0.92,
P G 0.0001. Fig. 3), but the size estimated in a [11C]MCYS
scan was 47 % greater than in a [11C]MET scan (slope of the
regression 1.47 ± 0.11).
Group 3
At 1 day after irradiation, the tumor uptake of [11C]MET
was already significantly reduced (SUVmean by 17 %,
SUVmax by 30 %), in contrast to the uptake of [11C]MCYS
(SUVmean − 4 %, SUVmax − 7 %, compare Tables 2 and
3). However, at 4 days after irradiation, the uptake of both
tracers showed a similar decline (SUVmean 13 to 16 %,
SUVmax 30 to 32 %). Radiotherapy had no significant
impact on the uptake of [11C]MET or [11C]MCYS in the
healthy brain (P = NS, both at 9 and 12 days).
Tumor sizes estimated from [11C]MET and [11C]MCYS
scans in untreated animals were closely correlated (Fig. 3),
but [11C]MCYS indicated a larger tumor volume than
[11C]MET in animals treated with radiotherapy (Table 4,
Fig. 4). At 1 day after irradiation, [11C]MCYS showed a
volume with increased uptake that was even larger than the
tumor volume observed in untreated rats (Table 4).
However, [11C]MCYS indicated a strong reduction in
(apparent) tumor volume between 9 and 12 days (i.e.,
between 1 and 4 days after irradiation), whereas [11C]MET
did not show any significant change in tumor volume
during this period. At 12 days p.i., a therapy-related
suppression of tumor growth was detected with both
Fig. 3 Tumor volume estimated from [11C]MCYS and
[11C]MET scans (same animal, same tumor, same scanning
day). The volume estimated with [11C]MCYS was on average
47 % larger.
Fig. 2 Kinetics of (a) [11C]MET and (b) [11C]MCYS derived
radioactivity in tumor (●) and in wound tissue (○).
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tracers, whereas untreated gliomas continued to grow
exponentially (Table 4). Tumor volume doubling times
estimated from [11C]MET and [11C]MCYS scans were 2.3
and 2.1 days, respectively.
Groups 4 and 5
Both radiolabeled probes showed some accumulation in
striatal lesions but similar uptake after injection of saline or
LPS (Table 5). Their lesioned-to-healthy striatum ratios were
not significantly different (Table 5). SUV values of
[11C]MCYS, both in lesioned striata and in the healthy
brain, were slightly higher than those of [11C]MET.
Although the lesioned-to-healthy striatum ratios of the
tracers were not significantly different, the lesion volume
estimated for LPS-injected striatum in [11C]MCYS scans
was more than 3-fold higher (P G 0.01) than in [11C]MET
scans (Table 5). [11C]MCYS scans indicated that injection of
LPS causes damage to a larger brain area than injection of
saline (P G 0.0001). This difference between saline and LPS
was not visualized by [11C]MET (Table 3).
Discussion
[11C]MCYS has been evaluated in a heterotopic mouse
model of hepatocellular carcinoma and in a human PET
study involving a patient with recurrent glioma [5]. Here, we
compared the uptake of [11C]MCYS and [11C]MET in an
orthotopic glioma model. The rat model which we employed
mimics the invasion and growth, as well as the neuro-
inflammation and leukocyte infiltration which occur in a
human glioblastoma [9, 13]. Our pilot study (group 1)
indicated rapid growth of implanted gliomas. Thus, each rat
in the following groups was scanned at rather short intervals
(6, 9, and 12 days) after inoculation.
The PET studies indicated a similar uptake of the two
tracers in untreated gliomas at 6, 8, and 9 days and a slightly
higher uptake of [11C]MCYS at 12 days after inoculation
(Table 2). However, [11C]MCYS showed also higher uptake
in healthy brain tissue than [11C]MET (Table 2). For this
reason, tumor-to-healthy brain ratios of [11C]MCYS were 19
to 26 % lower than of [11C]MET (Table 2). At short
intervals between the inoculation of tumor cells and the PET
scan (6 days), [11C]MET was strongly accumulated in the
wound on top of the skull and also in salivary glands and
nasal epithelium, in contrast to [11C]MCYS (Table 2, Fig. 1).
The strong accumulation of [11C]MET in healing wounds
and at the injection spot of the brain was a complicating
factor in the detection and delineation of small tumors.
Methionine is not only a substrate for protein synthesis but is
also involved in transmethylation [14]. The label of
[11C]MET may therefore end up in various phospholipids,
DNA, and RNA [2], in contrast to the label of [11C]MCYS
which is not incorporated into macromolecules during a PET
scan [5]. This difference in the metabolism of the two tracers
may explain why [11C]MET (but not [11C]MCYS) accumu-
lates in healing wounds.
We also examined the impact of radiotherapy on tracer
uptake in gliomas. Tumor-bearing rats were scanned 1 and
Table 3. Tracer uptake in rats which received radiotherapy (on day 8)













6 days p.i. 7 0.92 ± 0.10 1.02 ± 0.05 1.14 ± 0.20 1.18 ± 0.15 7 0.57 ± 0.03 0.81 ± 0.05
9 days p.i. 7 1.04 ± 0.12@ 1.19 ± 0.03& 1.34 ± 0.28@ 1.67 ± 0.14 7 0.63 ± 0.07 0.85 ± 0.04
12 days p.i. 7 1.03 ± 0.09@ 1.14 ± 0.05* 1.24 ± 0.21# 1.44 ± 0.19* 7 0.64 ± 0.05 0.85 ± 0.04
Uptake ratios Tumor-to-brain
N [11C]MET Mean ratio [11C]MCYS Mean ratio [11C]MET Max ratio [11C]MCYS Max ratio
6 days p.i. 7 1.61 ± 0.15 1.27 ± 0.08 1.81 ± 0.31 1.37 ± 0.22
9 days p.i. 7 1.66 ± 0.08* 1.41 ± 0.05 1.88 ± 0.18* 1.84 ± 0.15
12 days p.i. 7 1.62 ± 0.19# 1.33 ± 0.04* 1.76 ± 0.24* 1.56 ± 0.12
See the footer of Table 2 for used abbreviations
*P G 0.0001, #P G 0.001, @P G 0.005, and &P G 0.01 indicate significant differences between irradiated (Table 3) and untreated (Table 2) rats









6 days p.i. 7 17 ± 8 17 ± 6 28 ± 18 20 ± 11
9 days p.i. 7 68 ± 33 35 ± 13@ 112 ± 90! 197 ± 86$!
12 days p.i. 7 147 ± 83 30 ± 14* 278 ± 147! 131 ± 103&%
P.i. post inoculation
*P G 0.0001, @P = 0.005, &P G 0.01 and $P G 0.05 indicate significant differences between untreated and irradiated rats
!P G 0.005, %P G 0.01 indicate significant differences between [11C]MET and [11C]MCYS
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4 days after the application of a single X-ray fraction of
25 Gy on day 8 after inoculation. The uptake of both
tracers showed a significant decline after radiotherapy
(Table 3) which reflects a decrease of tumor metabolism.
In untreated animals, [11C]MCYS indicated 47 % larger
tumor volumes than [11C]MET (Fig. 3), but the close
correlation between [11C]MCYS and [11C]MET volumes
was lost after irradiation. In irradiated animals,
[11C]MCYS indicated 5- to 6-fold larger tumor volumes
than [11C]MET (Table 4). The tumor volume observed in
[11C]MCYS scans 1 day after irradiation was even much
(1.8-fold) larger than the tumor volume observed with
the same tracer in untreated rats (Table 4). The acute
increase in apparent tumor volume after irradiation that
we observed in [11C]MCYS but not in [11C]MET scans
seemed therefore to be related to a treatment-induced
artifact (increased blood flow, increased leakiness of the
blood-brain barrier, brain-infiltrating leukocytes) rather
than the presence of viable tumor cells.
Since apparent tumor volumes after radiotherapy may
be affected by tracer uptake in activated microglia, we
examined the uptake of [11C]MET and [11C]MCYS in a
neuroinflammation model. The LPS model which we
employed is associated with activated microglia and
infiltration of leukocytes after 3 days [10]. [11C]MCYS
showed a higher uptake than [11C]MET both in LPS-
injected and saline-injected striatum, but the uptake of
[11C]MCYS in healthy brain tissue was also higher. The
lesioned-to-intact striatum ratios of the two tracers were
therefore identical (Table 4). Tracer uptake in LPS-
injected and saline-injected striatum was similar. This
observation suggests that both tracers show negligible
Fig. 4 Sagittal and transaxial PET images of a single rat made 1 day after irradiation (9 days after inoculation of tumor cells).
Arrows point to the position of the tumor. The estimated tumor volume (area with increased tracer uptake) is much larger after
injection of (b) [11C]MCYS than after injection of (a) [11C]MET.
Table 5. Tracer uptake in animals with neuroinflammation

















LPS-injected (n = 9) 0.73 ± 0.08 1.03 ± 0.07* 0.86 ± 0.12 1.22 ± 0.19# 0.62 ± 0.06 0.85 ± 0.06* 0.65 ± 0.06 0.89 ± 0.05*
Saline-injected (n = 9) 0.70 ± 0.06 0.97 ± 0.13# 0.86 ± 0.16 1.14 ± 0.18@ 0.61 ± 0.05 0.84 ± 0.10* 0.65 ± 0.06 0.87 ± 0.10*










LPS-injected (n = 9) 1.17 ± 0.07 1.21 ± 0.06 1.32 ± 0.18 1.37 ± 0.20 13 ± 5 44 ± 27&
Saline-injected (n = 9) 1.15 ± 0.04 1.16 ± 0.06 1.33 ± 0.20 1.31 ± 0.20 13 ± 4 18 ± 10!
*P ≤ 0.0001, #P G 0.0005, @P G 0.005, and &P G 0.01 indicate significant differences between [11C]MET and [11C]MCYS
!P G 0.0001 indicates significant difference between LPS and saline
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accumulation in activated microglia. However, an inter-
esting difference was noted when the volume with
significant tracer accumulation was considered.
[11C]MET and [11C]MCYS indicated identical lesion
volumes in saline-injected animals, but [11C]MCYS
indicated a larger volume for LPS-injected striatum than
[11C]MET. The difference between LPS and saline was
thus detectable in [11C]MCYS but not in [11C]MET
scans (Table 4). Since the PET scans in the neuro-
inflammation model did not suggest a significant accu-
mulation of [11C]MCYS in leukocytes or activated
microglia, radiotherapy and LPS injection appear to
cause secondary damage to the area surrounding the
tumor or primary lesion which facilitates uptake of
[11C]MCYS but not of [11C]MET. The mechanism
underlying this facilitation is unknown and can only be
clarified by further study, e.g., by pathologic analysis of
the area with increased [11C]MCYS uptake, 1 day after
tumor irradiation.
Conclusion
[11C]MCYS has been proposed as an oncologic PET tracer
with greater tumor selectivity than [11C]MET. In support of
this claim, we observed a strong accumulation of [11C]MET
in salivary glands, Harderian glands, nasal epithelium, and
healing wounds whereas [11C]MCYS showed little accumu-
lation in such tissues. However, (1) the tumor-to-brain
contrast in [11C]MCYS scans was 19 to 26 % lower than
the tumor-to-brain contrast of [11C]MET. This difference in
image contrast was due to a higher uptake of [11C]MCYS in
brain tissue; (2) an acute, 2-fold increase of the apparent
tumor volume was observed in [11C]MCYS scans after
irradiation which appeared to be related to a treatment-
induced artifact; (3) the decrease of tumor metabolism
induced by radiotherapy was detected earlier in [11C]MET
than in [11C]MCYS scans; and (4) both [11C]MET and
[11C]MCYS showed negligible accumulation in LPS-
injected striatum, i.e., in activated microglia. For these
reasons, [11C]MCYS and [11C]MET appear to reflect
different aspects of in vivo biology. [11C]MCYS may offer
the advantage of lower background accumulation in extra-
cranial tissue whereas [11C]MET may exhibit a lower
normophysiological signal in the brain. Since the current
data were acquired in anesthetized animals, tracer distribu-
tion may be different in the absence of anesthesia. Future
studies should be aimed at elucidating the processes
affecting the uptake of both amino acids and identifying
the advantage of one compound over another in various
circumstances.
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